Inflammatory pathways in skin cells

Inflammatory pathways in skin cells refer to the complex network of intracellular and intercellular signaling cascades that mediate the skin's response to injury, pathogens, or autoimmune triggers. These pathways involve various cell types, including keratinocytes, fibroblasts, and resident immune cells like Langerhans cells and T-cells. Key molecular players include the NF-κB, JAK-STAT, and MAPK pathways, which regulate the expression of pro-inflammatory cytokines, chemokines, and adhesion molecules (Source: StatPearls, 'Physiology, Inflammation'). Dysregulation of these pathways is a hallmark of chronic inflammatory skin diseases such as psoriasis and atopic dermatitis, where overactive signaling leads to tissue damage and impaired barrier function (Source: NIH, 'Inflammatory Skin Diseases'). Pharmacological intervention typically targets specific components of these pathways, such as cytokine receptors or intracellular kinases, to restore immune homeostasis and alleviate clinical symptoms (Source: PubMed, 'Targeting signaling pathways in skin inflammation'). Because this term describes a broad biological process rather than a single protein or receptor, it is considered a pathway collection rather than a specific therapeutic target.

Other names

Cutaneous inflammatory signalingSkin inflammation pathwaysDermal inflammatory cascades

Inhibition of specific nodes within the pathways, such as Janus kinases (JAK), phosphodiesterase-4 (PDE4), or specific cytokines like IL-17, IL-23, and TNF-alpha.